Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. - Wikidata - awgldk - TriplyDB

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.

http://www.wikidata.org/entity/Q35062862

about

VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis Potential Coagulation Factor-Driven Pro-Inflammatory Responses in Ovarian Cancer Tissues Associated with Insufficient O₂ and Plasma Supply.In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies.Inhibition of pathological brain angiogenesis through systemic delivery of AAV vector expressing soluble FLT1.Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.Effects of calcitriol on random skin flap survival in rats Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.Tumour hypoxia causes DNA hypermethylation by reducing TET activity.Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC)Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.Addressing intra-tumoral heterogeneity and therapy resistance.Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.Vessel pruning or healing: endothelial metabolism as a novel target?Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Bioinspired Hydrogels to Engineer Cancer Microenvironments.Calcitriol promotes survival of experimental random pattern flap via activation of autophagy.Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support.Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients.Rethinking cancer nanotheranostics.Engineering and physical sciences in oncology: challenges and opportunities.Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.Astrocyte elevated gene-1 is overexpressed in non-small-cell lung cancer and associated with increased tumour angiogenesis.A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer.[Clinical Research on Albumin-bound Paclitaxel-based Therapy in Advanced Lung Cancer].TET enzymes as oxygen-dependent tumor suppressors: exciting new avenues for cancer management.The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma.Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.[Application of Bevacizumab in Non-small Cell Lung Cancer].Monitoring of tumor vascular normalization: the key points from basic research to clinical application

P2860

Q26770678-F0A9E3D7-14AC-4146-89C9-4EF63F13C043 Q26777144-B9C4F87C-2C83-4290-A3F5-ED92CC3D0F12 Q26799981-771B285F-2D2C-480D-AB31-908C89B493EF Q28079663-E798E131-154B-4EE6-9CA8-A470BD2AC1C8 Q33618582-16923E9E-D100-4D1A-ABC2-ED228BE91FCE Q33624680-08EC78CF-2DE3-4387-8176-D6B09A7C6651 Q33819576-14B61FA9-8619-4418-90D8-AA7EF0E5FB82 Q36258054-0E3572D3-86BB-4CE4-B5BD-1632A5AD4CA2 Q36306066-D0D23B0C-AB49-42F2-893A-019EE51E9CB3 Q36432630-1FADB8A5-F750-4005-AA2B-4FAC97F8CEA8 Q37458763-0F8A2236-6CF1-4467-ADC9-93F0AED916D8 Q37461422-3302FC02-5AFC-4DF8-A618-7B5DA5E95214 Q37463942-2E5AC833-7D4D-4D32-B218-265685F491D5 Q37539775-1D7658BC-4205-4633-AE70-8FB02625AA55 Q37562355-D6DF50C7-EAB0-4509-88A2-FACD3394E7E7 Q37690917-E5272AA9-E6AF-4CB3-9CD9-46D8B505E986 Q38823179-54957BCC-B093-46DC-94DD-A05C760E74D1 Q39004424-EE3B096A-4BD4-4724-8EEB-8BF378BECBDC Q39024164-FF3DCF0A-DC3D-4E18-A8F3-1C5B20853CB7 Q39210287-B6DC1733-E175-4823-A268-15919CC38961 Q39386471-EA4FF3A9-A4DF-4077-8F17-EF24E5FA2D29 Q41549294-4B9E1EB8-F3CB-4445-867F-01981594B235 Q42332154-584F8EC8-5977-48EA-8FB0-4A9DB13934AF Q42332276-E6189E6A-F8D6-40E1-88D6-3D52B931A963 Q42640884-6B29BF3A-5E1D-4B60-A490-5542FB23110D Q47244877-0DC1892A-ACDD-4165-A845-BB5442E980EC Q47346043-A221075F-EA0D-40B1-BBB8-A6AA51FDAE16 Q50096986-BE568DA6-461A-4984-BABA-03AABF293E30 Q51597242-2DBDEC29-CEA0-4291-B0F9-A40EB4AC0E23 Q52576035-AEFF7063-FFEC-4AC3-AF6F-72B96079D797 Q53145703-E60DCC25-6F5F-40A9-8AE0-BDFCA2225320 Q53762480-93283612-82AA-4B7A-9896-C1D277E85DAB Q54978333-ACB33409-E25F-4B70-8E41-6544DE77C32D Q55190117-9D18D624-D04B-48AF-A58E-84EB138E3B58 Q55556494-4FEA4BE7-1C19-4B6F-9D2C-8AE6FFB0D848 Q57484416-5DE9AB21-71A6-4C54-9B98-3436724A684D

P2860

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.

http://www.wikidata.org/entity/Q35062862

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Improved tumor vascularization ...... with survival in lung cancer.

@ast

Improved tumor vascularization ...... with survival in lung cancer.

@en

type

label

Improved tumor vascularization ...... with survival in lung cancer.

@ast

Improved tumor vascularization ...... with survival in lung cancer.

@en

prefLabel

Improved tumor vascularization ...... with survival in lung cancer.

@ast

Improved tumor vascularization ...... with survival in lung cancer.

@en

P1433

Q35062862-FF22C5EF-9956-448E-BDA2-6630520AAA55

P1476

Q35062862-7E96504A-536F-493A-969E-58217E372F2F

P2093

Q35062862-2680DD8D-3F3A-405E-9CB4-8A47099A1600

Q35062862-2BE2DFD1-8999-407D-80F3-78B5DD1D65F0

Q35062862-3D8D36CE-5F25-433D-BCA7-8FFA9E0073D1

Q35062862-4C0B814B-8B3E-4064-B63C-3224F2C65DAB

Q35062862-615FC7C0-AE24-46A7-BD9D-FD52870A98D9

Q35062862-6ADA1F22-84A1-4913-9F87-1F566F8D1FDF

Q35062862-7151EC5A-B5FC-4C41-B5CE-6D0E647E2126

Q35062862-B0B6E6FE-C303-4D94-8168-EEE4051957B1

Q35062862-BCFBF520-56EB-4EC9-AE6B-707F2B77812F

Q35062862-C19073E5-B42E-4DD9-9FD0-1CD348B0A7C6

P2860

Q35062862-0A0A5FFB-BB77-4327-A0E0-BEE4D4A44208

Q35062862-2C5CB1ED-26D6-44BB-9268-EDE183A5A863

Q35062862-2F7998D9-0885-40D8-B06B-65A6A35531E2

Q35062862-3D0B5635-538F-4345-A301-E663DC27A682

Q35062862-418A3204-ACBD-49B3-BCCA-A6DF901C8CC0

Q35062862-4EDC8BF4-050A-4295-877A-1F776DB6FA22

Q35062862-50A05621-DBE1-40F5-9265-500DD924352C

Q35062862-5405C59D-3EA0-4607-BE6E-92F6DE039205

Q35062862-561EBD03-8D61-4A15-A997-5703F0C2B63F

Q35062862-5A378074-0F99-444C-B3ED-0B4157748412

P304

Q35062862-EBC33A78-BE32-4C41-A1CE-572FB7BC0C88

P31

Q35062862-8094137C-5DB1-4B0E-83EE-6E96B089D1B3

P356

Q35062862-89584D5C-B7E7-4EAB-BB34-C2239ABA8207

P407

Q35062862-3B3A40EC-9E56-460D-AC47-869E528A2907

P433

Q35062862-C783242F-C3E6-409E-950E-ABF335C3EB68

P478

Q35062862-6F7FF673-BCE9-4783-8188-25170F546A30

P50

Q35062862-304BA902-96B0-4735-9D92-C49599FF4F8C

Q35062862-8C22834F-DB30-440A-8DEA-E79ED83BDC87

P577

Q35062862-6D25F415-599F-4732-B077-8E66AA4F7F28

P5875

Q35062862-77ACC86E-B6BE-4961-8097-65BB405813C3

P698

Q35062862-E5FDBB94-0F15-4A0D-8B1C-51BD108BE369

P932

Q35062862-7038E99C-0F32-47FD-A1D2-E02BA93ABA51

P356

PNAS.1424024112

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Improved tumor vascularization ...... with survival in lung cancer.

@en

P2093

Alice T Shaw

http://www.w3.org/2001/XMLSchema#string

Dan G Duda

http://www.w3.org/2001/XMLSchema#string

Dushyant V Sahani

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

Jennifer S Temel

http://www.w3.org/2001/XMLSchema#string

Joel W Neal

http://www.w3.org/2001/XMLSchema#string

Lecia V Sequist

http://www.w3.org/2001/XMLSchema#string

Marek Ancukiewicz

http://www.w3.org/2001/XMLSchema#string

Panos Fidias

http://www.w3.org/2001/XMLSchema#string

Rakesh K Jain

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer

Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)

Molecular mechanisms and clinical applications of angiogenesis

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Prediction of creatinine clearance from serum creatinine

Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.

Normalization of the vasculature for treatment of cancer and other diseases.

P304

1547-1552

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1424024112

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Nathan A Pennell

P577

2015-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272406452

http://www.w3.org/2001/XMLSchema#string

P698

25605928

http://www.w3.org/2001/XMLSchema#string

P932

4321320

http://www.w3.org/2001/XMLSchema#string